Budipine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Budipine
Budipine.svg
Systematic (IUPAC) name
1-tert-butyl-4,4-diphenylpiperidine[1]
Clinical data
AHFS/Drugs.com International Drug Names
Legal status ?
Identifiers
CAS number 57982-78-2 YesY
ATC code N04BX03
PubChem CID 68778
ChemSpider 62021 YesY
UNII L9026OPI2Z YesY
KEGG D07306 YesY
ChEMBL CHEMBL334491 YesY
Chemical data
Formula C21H27N 
Mol. mass 293.446 g/mol
 YesY (what is this?)  (verify)

Budipine is an antiparkinson agent.

Its mechanism of action is not well characterized.[2] It is believed to be an NMDA receptor antagonist,[3] however, promoting the synthesis of dopamine.[4]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[5]

See also[edit]

References[edit]

  1. ^ Martndale: The Complete Drug Reference, 35th Ed.
  2. ^ Reichmann H (October 2006). "Budipine in Parkinson's tremor". J. Neurol. Sci. 248 (1-2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759. 
  3. ^ J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
  4. ^ "umm.edu". 
  5. ^ Przuntek H, Bittkau S, Bliesath H, et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.